Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity (original) (raw)

• Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329–336 (2005).
  Article CAS Google Scholar
• Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132 (2008).
  Article CAS Google Scholar
• Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).
  Article CAS Google Scholar
• Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007).
  Article CAS Google Scholar
• Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
  Article CAS Google Scholar
• Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199–204 (2003).
  Article CAS Google Scholar
• Ma, H., Deacon, S. & Horiuchi, K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin. Drug Discov. 3, 607–621 (2008).
  Article CAS Google Scholar
• Smyth, L.A. & Collins, I. Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol. 2, 131–151 (2009).
  Article Google Scholar
• Goldstein, D.M., Gray, N.S. & Zarrinkar, P.P. High-throughput kinase profiling as a platform for drug discovery. Nat. Rev. Drug Discov. 7, 391–397 (2008).
  Article CAS Google Scholar
• Miduturu, C.V. et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem. Biol. 18, 868–879 (2011).
  Article CAS Google Scholar
• Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001–1010 (2004).
  Article CAS Google Scholar
• Morphy, R., Kay, C. & Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today 9, 641–651 (2004).
  Article CAS Google Scholar
• Metz, J.T. et al. Navigating the kinome. Nat. Chem. Biol. 7, 200–202 (2011).
  Article CAS Google Scholar
• Dodson, C.A. et al. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochem. J. 427, 19–28 (2010).
  Article CAS Google Scholar
• Graczyk, P.P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 50, 5773–5779 (2007).
  Article CAS Google Scholar
• Bamborough, P., Drewry, D., Harper, G., Smith, G.K. & Schneider, K. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J. Med. Chem. 51, 7898–7914 (2008).
  Article CAS Google Scholar
• Faivre, S., Djelloul, S. & Raymond, E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 33, 407–420 (2006).
  Article CAS Google Scholar
• Morphy, R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 53, 1413–1437 (2010).
  Article CAS Google Scholar
• Knight, Z.A., Lin, H. & Shokat, K.M. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130–137 (2010).
  Article CAS Google Scholar
• Cockerill, S. et al. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2. Bioorg. Med. Chem. Lett. 11, 1401–1405 (2001).
  Article CAS Google Scholar
• Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547–566 (2009).
  Article CAS Google Scholar
• Zhang, Q. et al. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. J. Am. Chem. Soc. 128, 2182–2183 (2006).
  Article CAS Google Scholar
• Lee, J.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746 (1994).
  Article CAS Google Scholar
• Cuny, G.D. et al. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg. Med. Chem. Lett. 20, 3491–3494 (2010).
  Article CAS Google Scholar
• Huertas, D. et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene published online, doi:10.1038/onc.2011.335 (1 August 2011).
  Article CAS Google Scholar
• Patnaik, D. et al. Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J. Biomol. Screen. 13, 1025–1034 (2008).
  Article CAS Google Scholar
• Mencher, S.K. & Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 5, 3 (2005).
  Article Google Scholar
• Liao, J.K., Seto, M. & Noma, K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 50, 17–24 (2007).
  Article CAS Google Scholar
• Yarrow, J.C., Totsukawa, G., Charras, G.T. & Mitchison, T.J. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem. Biol. 12, 385–395 (2005).
  Article CAS Google Scholar
• Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621–637 (2005).
  Article CAS Google Scholar
• Fedorov, O., Muller, S. & Knapp, S. The (un)targeted cancer kinome. Nat. Chem. Biol. 6, 166–169 (2010).
  Article CAS Google Scholar
• Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275–282 (2002).
  Article CAS Google Scholar
• Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
  Article CAS Google Scholar
• Yee, T.W. & Hastie, T.J. Reduced-rank vector generalized linear models. Stat. Modelling 3, 15–41 (2003).
  Article Google Scholar
• van der Loo, M.P.J. Distribution-based outlier detection for univariate data. Discussion paper 10003 (Statistics Netherlands, The Hague, 2010).
• Cheng, Y. & Prusoff, W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108 (1973).
  Article CAS Google Scholar